ARCELLX Q1 2026 Earnings Preview: Recent $ACLX Insider Trading, Hedge Fund Activity, and More
ARCELLX (ACLX) is set to release its Q1 2026 earnings on May 18th, with analysts forecasting $7.65 million in revenue and a -$1.09 EPS. The article provides a detailed look at recent insider trading, showing 12 sales and no purchases in the last six months, totaling millions in shares sold. It also highlights institutional investor activity, noting significant reductions and additions to ACLX holdings, alongside recent "Buy" and "Overweight" analyst ratings and price targets with a median of $115.0.
Arcellx (ACLX) Amendment shows Vestal Point and Wilder report 0% ownership
Arcellx, Inc. (ACLX) received an Amendment No. 1 to Schedule 13G/A from Vestal Point Capital, LP and Ryan Wilder, indicating their reported ownership of the company's common stock is 0%. This filing confirms that the reporting persons beneficially own 0.00 shares, reflecting five percent or less of the class, and is considered a routine informational disclosure. The amendment was signed on May 15, 2026, and does not suggest any change in control or immediate major market impact.
The Other Side of Arcellx’s $7.8 Billion Exit: What the Gilead Buyout Means for Maryland’s Biotech Workforce
Gilead Sciences' $7.8 billion acquisition of Arcellx, while a strategic win for CAR-T therapies, entails 192 job eliminations, including 84 in Rockville, Maryland, as operations are integrated. This talent release is seen as a paradoxical boost for Maryland's biotech ecosystem, providing experienced professionals who can fuel new startup ventures and innovation cycles. The article argues that this redistribution of highly skilled individuals, especially in cell and gene therapy, will strengthen the region's biotech leadership and operational capabilities.
[15-12G] Arcellx, Inc. SEC Filing
Arcellx, Inc. has filed Form 15-12G with the SEC, certifying the termination of its registration under Section 12(g) of the Securities Exchange Act of 1934 or suspension of the duty to file reports under Sections 13 and 15(d). The filing indicates the company is relying on rules 12g-4(a)(1) and 12h-3(b)(1)(i) and has one holder of record as of the certification date. This action follows recent news of Gilead Sciences completing its acquisition of Arcellx.
When Gilead Cuts 108 Jobs at Arcellx, Your Trial Feels It Before You Know Why
Gilead's acquisition of Arcellx and the subsequent layoff of 108 employees are causing significant operational disruptions for clinical trial sites, especially those involved in the time-sensitive CAR-T programs for multiple myeloma. These workforce reductions lead to monitoring continuity gaps, activation delays, and loss of institutional knowledge, jeopardizing trial timelines and patient enrollment momentum. The article advises sites to proactively seek clarification on new contacts and authorities, urging sponsors to prioritize site-level stability to meet commercial milestones.
After Arcellx buyout close, Gilead trims 108 jobs at CAR-T biotech's Redwood City outpost
Gilead Sciences is laying off 108 workers from Arcellx's Redwood City site following its $7.8 billion acquisition of the CAR-T biotech. The job cuts are part of integration efforts after the deal closed last Tuesday, impacting approximately half of Arcellx's workforce. Gilead expects an FDA decision on Arcellx's anito-cel, a BCMA-directed CAR-T therapy, by December 2026 for fourth-line multiple myeloma.
Gilead completes Arcellx buy, securing myeloma treatment anito-cel
Gilead has finalized its $7.8 billion acquisition of Arcellx, integrating the companies to accelerate the development of anito-cel, an experimental CAR T-cell therapy for multiple myeloma. The acquisition gives Gilead's Kite full control over the therapy, streamlining its progress toward market. Anito-cel, which targets the BCMA protein on myeloma cells, has shown promising results in Phase 2 studies, with a Phase 3 trial currently recruiting patients.
Cell therapy weekly: Gilead Sciences acquires Arcellx for $7.8 billion
This week in cell therapy, Ray Therapeutics received PRIME designation for its gene therapy for retinitis pigmentosa, and Orca Bio's T-cell therapy received RMAT designation from the FDA. Gilead Sciences acquired Arcellx for approximately $7.8 billion, gaining full ownership of anitocabtagene autoleucel, a CAR T-cell therapy for multiple myeloma. Additionally, Cellares and Cabaletta Bio entered a 10-year commercial supply agreement for an autoimmune CAR-T therapy, highlighting advancements in scalable manufacturing for such treatments.
Arcellx, Inc. Financial Disclosures & Filings
This page provides a comprehensive list of Arcellx, Inc.'s financial disclosures and regulatory filings, including quarterly and annual earnings reports, 10-K and 10-Q filings, and event transcripts from various conferences. The documents span from 2021 to anticipated filings in 2026, offering investors insight into the company's performance and strategy. Users can explore these resources to support informed investment decisions.
Pictet Asset Management Holding SA Decreases Stake in Arcellx, Inc. $ACLX
Pictet Asset Management Holding SA significantly reduced its stake in Arcellx, Inc. (ACLX) by 18.6% in the fourth quarter, selling 78,193 shares and retaining 342,612 shares valued at approximately $22.34 million. This move coincides with an insider sale by Rami Elghandour, who sold 89,916 shares worth over $10 million, decreasing his ownership by nearly a quarter. Analysts have largely shifted to a "Hold" rating for Arcellx, with a consensus target price of $111.87, following the company's recent earnings that met EPS estimates but showed a substantial revenue miss.
Gilead buys Arcellx (ACLX) for $115 per share plus $5 CVR
Gilead Sciences has completed its acquisition of Arcellx (ACLX) for $115 per share in cash, plus a contingent value right (CVR) of an additional $5 upon achieving a specified milestone. This transaction was finalized on April 28, 2026, with Gilead's subsidiary purchasing all outstanding Arcellx shares and merging with the company, making Arcellx a wholly owned subsidiary. As a result, major shareholder New Enterprise Associates no longer holds any beneficial ownership in Arcellx.
Arcellx, Inc. (NASDAQ:ACLX) Short Interest Down 20.7% in April
Arcellx, Inc. (NASDAQ:ACLX) experienced a 20.7% decrease in short interest in April, bringing the total to 1,800,274 shares and a short-interest ratio of 2.5 days. This occurred amidst several analyst downgrades, including from Wells Fargo, UBS, and TD Cowen, resulting in an average "Hold" rating and a consensus price target of $111.87. Additionally, insider Rami Elghandour sold a significant portion of his shares, while institutional investors maintain a high ownership percentage.
Gilead Completes $7.8-Bn Acquisition of Arcelix
Gilead Sciences has finalized its $7.8-billion acquisition of Arcellx, an oncology-focused bio/pharmaceutical company. This acquisition follows an existing collaboration between Gilead's subsidiary, Kite, and Arcellx to co-develop anitocabtagene autoleucel, a CAR T-cell therapy for multiple myeloma. The deal involved Gilead acquiring most of Arcellx's common stock for $115 per share plus a contingent value right tied to future sales of the therapy.
Gilead completes Arcellx merger; Arcellx (NASDAQ: ACLX) deregisters S-3
Arcellx, Inc. (NASDAQ: ACLX) has filed a post-effective amendment to deregister all unsold securities under its Form S-3 following its merger with Gilead Sciences, Inc. on April 28, 2026. This action formalizes the termination of offerings under the registration statement, making Arcellx a wholly owned subsidiary of Gilead. The filing indicates no securities remain registered under the specified registration number after this amendment.
Gilead buys Arcellx (NASDAQ: ACLX) in $7.1B cash and CVR deal
Gilead Sciences has completed its acquisition of Arcellx for approximately $7.1 billion. Arcellx stockholders received $115.00 per share in cash plus one contingent value right (CVR) that could pay an additional $5.00 if anito-cel sales reach $6.0 billion by December 31, 2029. Arcellx is now a wholly-owned subsidiary of Gilead, its public listing is being terminated, and its governance has been restructured.
Wilson Sonsini Advises Arcellx on Merger with Gilead Sciences
Wilson Sonsini represented Arcellx in its recent acquisition by Gilead Sciences, serving as the lead legal advisor. This highlights the firm's expertise in life sciences M&A and its long-term support for Arcellx, from its formation and IPO to its collaboration with Kite Pharma.
Arcellx (ACLX) director-linked fund exits as Gilead buyout closes
A fund associated with Arcellx director Jill Carroll, SR One Capital Fund I Aggregator, LP, tendered 1.48 million shares of Arcellx common stock as part of Gilead Sciences' acquisition. The transaction, reported in a Form 4 filing, involved tendering shares for $115.00 cash plus a contingent value right, and the cancellation of stock options for cash and CVRs. Following these transactions, neither Carroll nor the affiliated fund hold any Arcellx common stock or options, signaling a complete exit due to the merger.
Gilead deal cashes out Arcellx (NASDAQ: ACLX) director options
Arcellx director Olivia C. Ware reported the disposition of four stock option grants totaling 65,450 options as part of the merger agreement with Gilead Sciences. These options, all with exercise prices below the $115 Closing Amount, were canceled and converted into cash payments and contractual contingent value rights. Following the transaction, Ware holds zero options from these grants.
Arcellx (ACLX) director’s shares and options cashed out in Gilead deal
Arcellx director David Charles Lubner has fully exited his position in the company as part of the Gilead acquisition. He tendered 21,659 shares of common stock for $115.00 cash plus one contingent value right (CVR) per share, and all his in-the-money stock options were canceled and converted into cash and CVRs. Following these transactions, Lubner holds no Arcellx securities.
[Form 4] Arcellx, Inc. Insider Trading Activity
Arcellx director Andrew H. Galligan reported dispositions of Arcellx common stock and stock options due to the company's merger with Gilead Sciences. Galligan's trust tendered 5,000 shares for $115.00 cash per share plus a contingent value right, and stock options were canceled and converted into cash and contingent value rights. This Form 4 filing indicates no remaining holdings for Galligan in this context after the transactions.
[Form 4] Arcellx, Inc. Insider Trading Activity
Arcellx, Inc. director Kavita Patel reported the cancellation of multiple stock option awards due to Arcellx's merger with Gilead Sciences. Five blocks of stock options covering a total of 76,234 shares across various exercise prices were disposed of on April 28, 2026. This action converted them into a right to receive a lump-sum cash payment and a contingent value right for each share, as per the merger agreement.
Arcellx (ACLX) CMO reshapes stock and options in Gilead deal
Arcellx (ACLX) Chief Medical Officer Christopher Heery reported significant changes to his equity holdings following the company's merger with Gilead Sciences. He tendered 23,749 common shares and had all outstanding stock options and restricted stock units canceled and converted into cash payments and contingent value rights. Additionally, Heery received a new grant of 45,138 performance-based restricted stock units.
Gilead completes $7.8 billion acquisition of Arcellx
Gilead Sciences Inc. has completed its acquisition of Arcellx Inc. for approximately $7.8 billion, acquiring all outstanding shares at $115 cash per share plus a contingent value right of $5. This grants Gilead full ownership of anito-cel, an investigational CAR T-cell therapy for multiple myeloma. The acquisition is expected to impact Gilead's GAAP and non-GAAP diluted earnings per share in 2026 and 2027, with accretion anticipated in 2028 and beyond, subject to FDA approval for anito-cel.
Are medical stocks lagging Arcellx (ACLX) this year?
The article poses a question about whether medical stocks are underperforming compared to Arcellx (ACLX) this year. This implies a comparison of financial performance within the medical sector, likely focusing on stock returns or growth.
Arcellx (ACLX) details 2025 executive pay and board structure
Arcellx (ACLX) filed an amended 10-K detailing its board structure, governance, and executive compensation for 2025. The company's eight-member board is majority independent and diverse, with 50% women directors. Executives received 150% of target bonuses for achieving financial, manufacturing, clinical, commercial, and research goals, including BLA submission for anito-cel and pipeline advancements.
Arcellx, Inc. (NASDAQ:ACLX) Given Consensus Recommendation of "Hold" by Analysts
Analysts have issued a consensus "Hold" recommendation for Arcellx, Inc. (NASDAQ:ACLX) based on reports from nineteen research firms, with an average 12-month price target of $111.87. This follows several ratings downgrades and one upgrade to "Strong-Buy." The company recently reported in-line EPS but missed revenue expectations and remains unprofitable, trading near its 12-month high.
Arcellx Inc stock hits all-time high at 115.13 USD
Arcellx Inc. shares have reached an all-time high of $115.13, reflecting significant investor confidence and a remarkable 80.7% total return over the past year. However, the stock appears overvalued according to InvestingPro analysis, despite analysts revising earnings upward for the upcoming period. This surge comes amid Gilead Sciences' proposed acquisition of Arcellx for $7.8 billion, which has led to several analyst downgrades to align with the offer price.
Arcellx Inc stock hits all-time high at 115.13 USD By Investing.com
Arcellx Inc. (ACLX) reached an all-time high of $115.13 per share, reflecting strong investor confidence with an 80.7% total return over the past year. This milestone comes amidst news of Gilead Sciences acquiring Arcellx for approximately $7.8 billion, leading to analyst downgrades that align price targets with the acquisition offer. Despite being considered overvalued by InvestingPro analysis, the company's growth prospects are highlighted by upward earnings revisions from analysts.
Gilead (NASDAQ: ACLX) offers $115/share plus $5 CVR tied to $6B anito‑cel sales
Gilead has offered to acquire Arcellx (ACLX) for $115 per share in cash, along with a $5 Contingent Value Right (CVR). This CVR will be paid out on March 31, 2030, if the cumulative worldwide net sales of Arcellx's anito-cel product exceed $6.0 billion by December 31, 2029. The deal is detailed in an amended Schedule 14D-9 filing, which also addresses shareholder litigation and provides updated financial analysis inputs from Centerview.
Gilead Leans Further Into Oncology With Arcellx And Tubulis Deals
Gilead Sciences has completed its US$7.8 billion acquisition of Arcellx and announced a deal to acquire Tubulis GmbH, signifying a strategic shift towards oncology. These moves aim to diversify Gilead's portfolio beyond its strong HIV and antiviral franchises, entering the targeted cancer treatment market with cell therapies and antibody-drug conjugates. While these deals offer potential for long-term revenue growth and reduced reliance on legacy products, they also introduce integration and clinical trial risks, as well as increased R&D and manufacturing costs.
Trading the Move, Not the Narrative: (ACLX) Edition
This article provides an analysis of Arcellx Inc. (ACLX) with neutral near and mid-term readings and a long-term positive bias, though it notes elevated downside risk. It outlines three AI-generated trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, complete with entry zones, targets, and stop losses. The analysis also includes multi-timeframe signal analysis indicating support and resistance levels.
Gilead Leans Further Into Oncology With Arcellx And Tubulis Deals
Gilead Sciences has finalized its US$7.8 billion acquisition of Arcellx and announced an agreement to acquire Tubulis GmbH, signaling a significant push into oncology. These strategic moves aim to diversify Gilead's portfolio beyond its strong HIV and antiviral franchises, focusing on cell therapy and antibody drug conjugate technologies. While presenting potential long-term revenue sources, these acquisitions also introduce execution and integration risks that investors will closely monitor.
Gilead Leans Further Into Oncology With Arcellx And Tubulis Deals
Gilead Sciences has finalized its US$7.8 billion acquisition of Arcellx and announced a deal to acquire Tubulis GmbH, signaling a significant push into oncology. These strategic moves aim to diversify Gilead’s portfolio beyond its established antiviral therapies, focusing on cell therapy and antibody drug conjugates. Investors will be closely watching the execution and clinical progress of these acquisitions to assess their long-term impact on Gilead's growth and market position.
Gilead extends Arcellx tender offer again
Gilead Sciences has extended its tender offer for all outstanding shares of Arcellx's common stock. The new expiration date is 5:00 p.m. ET on May 3, 2026, unless further extended. All other terms and conditions of the tender offer remain unchanged.
Arcellx (ACLX) CFO exercises options, lifting direct stake to 67,048 shares
Arcellx (ACLX) CFO Michelle Gilson exercised stock options to acquire 38,110 shares of Common Stock at $8.66 per share, increasing her direct holdings to 67,048 shares. An additional 5,000 shares are held indirectly through a family charitable foundation. These transactions are compensation-related under Arcellx's 2022 Equity Incentive Plan, with no open-market sales reported.
Gilead Receives All Required Regulatory Approvals for the Acquisition of Arcellx and Extends Tender Offer
Gilead Sciences, Inc. announced that it has obtained all necessary regulatory approvals for its acquisition of Arcellx, with the Australian Competition and Consumer Commission's decision now being subject to a 14-day waiting period. Consequently, Gilead has extended the tender offer for Arcellx shares until April 27, 2026, maintaining the original purchase price of $115.00 per share plus a contingent value right. As of April 16, 2026, approximately 17.5% of Arcellx's outstanding shares had been tendered.
Gilead extends $115 takeover offer for Arcellx (NASDAQ: ACLX) to Apr 27
Gilead has extended its tender offer to acquire Arcellx (ACLX) until April 27, 2026, at 5:00 p.m. ET. The offer remains $115.00 per share plus a contingent value right (CVR) of $5.00, payable if anito-cel sales exceed $6.0 billion by the end of 2029. All regulatory approvals have now been obtained, with the final ACCC waiting period expiring on April 27, 2026.
Arcellx (NASDAQ:ACLX) Reaches New 52-Week High - Should You Buy?
Arcellx (NASDAQ:ACLX) has reached a new 52-week high of $115.04, trading on heavy volume. Despite this, the company remains unprofitable with a recent revenue miss, and analyst ratings are mixed with a consensus "Hold" and a price target below the current trading level. An insider sale of over $10 million in shares was reported, while institutional investors own approximately 96% of the stock.
Arcellx stock hits all-time high of 114.95 USD
Arcellx Inc. (ACLX) stock recently reached an all-time high of $114.95, marking a significant milestone driven by strong investor confidence and a 76% year-to-date return. This surge comes amid Gilead Sciences' announced acquisition of Arcellx for approximately $7.8 billion, leading to several analyst downgrades to "Hold" or "Neutral" with price targets around the acquisition offer price, signaling the market's response to the deal terms. Despite being potentially overvalued according to InvestingPro, analysts project a 173% sales growth for Arcellx in the current year.
Arcellx stock hits all-time high of 114.95 USD By Investing.com
Arcellx Inc. (ACLX) stock reached an all-time high of $114.95, reflecting significant investor confidence and a 76% year-to-date return, though InvestingPro's Fair Value analysis suggests it may be overvalued. The company anticipates a 173% surge in sales this year, but recent analyst downgrades to "Hold" or "Neutral" followed Gilead Sciences' proposed $7.8 billion acquisition of Arcellx, which offers $115 per share plus a contingent value right.
Arcellx, Inc. (NASDAQ:ACLX) Short Interest Update
Arcellx, Inc. (ACLX) saw a significant 51.7% decrease in short interest in March, totaling 2,269,775 shares, resulting in a short-interest ratio of 1.5 days. Insiders sold 109,366 shares worth about $11.53 million, reducing their ownership to 8.35%, while institutional investors, including T. Rowe Price, increased their holdings, now collectively owning approximately 96.03% of the stock. Analysts currently rate Arcellx as a "Hold" with an average target price of $111.87.
Gilead Less M&A Happy Now but Door Still Open for ‘Compelling’ Opportunities
Gilead Sciences CFO Andrew Dickinson stated that the company is unlikely to pursue more sizable M&A this year after completing three significant acquisitions totaling $14.77 billion. Despite the recent spree, which includes Arcelle, Ouro Medicine, and Tubulis GmbH, Gilead will remain open to strategic acquisitions if compelling opportunities arise, focusing primarily on integrating its new assets. CEO Daniel O’Day emphasized that these deals reflect finding the right companies in quick succession, not a lack of confidence in Gilead's existing pipeline.
Gilead Acquisition Spree Continues With $3 Billion Tubulis Deal
Gilead Sciences, Inc. announced the acquisition of Tubulis GmbH for $3.15 billion upfront, with potential additional milestone payments, to bolster its oncology pipeline through Tubulis' antibody-drug conjugate (ADC) programs. This deal follows other recent acquisitions, including Ouro Medicines and Arcellx Inc., indicating a broader strategy to expand Gilead's portfolio in both oncology and inflammation. Despite the acquisition news, Gilead's shares were down, with technical indicators showing mixed signals for the stock's short-term and intermediate-term performance, though a positive long-term outlook remains.
Gilead Sciences Details Tubulis, Ouro, Arcellx Deals as Pipeline Catalyst, 2026 Updates Loom
Gilead Sciences has outlined its strategic acquisitions of Tubulis, Ouro Medicines, and Arcellx, aiming to strengthen its late-stage pipeline in oncology, virology, and inflammation. These deals are expected to close in Q2 2026, with limited impact on 2026 operating expenses and funding primarily through cash and a short-term loan, supplemented by senior unsecured notes for Tubulis. The company anticipates multiple Phase 3 readouts in 2026 and up to ten new launches through 2027, with no major loss of exclusivity until 2036.
GILD: Acquisitions of Tubulis, Ouro, and Arcellx drive pipeline growth and market expansion
Gilead Sciences (GILD) has completed three acquisitions – Tubulis, Ouro, and Arcellx – to enhance its R&D and commercial reach in oncology and inflammation. These deals, funded by cash and short-term loans, aim to add best-in-class assets to Gilead's pipeline. Integration and regulatory approvals for these acquisitions are anticipated by Q2 2026.
With 3 acquisitions to digest, Gilead shifts focus from M&A to pipeline that has 'never been stronger'
Gilead Sciences has completed three major acquisitions in just six weeks, bringing CAR-T company Arcellx, T-cell engager-focused Ouro Medicines, and ADC biotech Tubulis into its portfolio. Following these deals, the company is now shifting its focus from further M&A to integrating these new assets and developing its pipeline, which CEO Daniel O’Day and Chief Medical Officer Dietmar Berger believe is the strongest in its history. The acquisitions are expected to significantly enhance Gilead's presence in oncology and autoimmune conditions, with promising lead assets like Tubulis’s TUB-040 and Ouro’s OM336, and the imminent launch of Arcellx’s anito-cel.
(ACLX) Volatility Zones as Tactical Triggers
This article analyzes Arcellx Inc. (ACLX) using AI models, identifying neutral near and mid-term readings but a positive long-term bias. It outlines three distinct institutional trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, complete with entry zones, targets, and stop losses. The analysis highlights an elevated downside risk due to a lack of additional long-term support signals.
Gilead Sciences Expands Pipeline with Tubulis, Ouro, and Arcellx Deals
Gilead Sciences has announced strategic acquisitions of Tubulis, Ouro Medicines, and Arcellx to strengthen its pipeline across oncology, virology, and inflammation. These deals introduce an ADC platform, an autoimmune T-cell engager, and a BCMA cell therapy, aiming for up to 10 new product launches by 2027. The company emphasizes that these transactions align with its business development strategy and will be followed by integration efforts.
Gilead Extends Tender Offer for Arcellx as Biotech M&A Sentiment Faces a Reality Check
Gilead Sciences has extended its tender offer to acquire Arcellx until April 24, 2026, after only 7.5% of Arcellx shares were tendered by the initial deadline. This delay highlights increasing caution among investors and stricter regulatory scrutiny in the biotech M&A market, despite the deal's strategic importance to Gilead's oncology expansion. The situation serves as a case study for the 2026 biotech M&A landscape, where contingent value rights are frequently used to mitigate risk.
Key facts: Gilead Extends Arcellx Deal; $115+CVR; HIV Coverage Varies
Gilead has extended its tender offer for Arcellx until April 24, 2026, for $115 cash per share plus a contingent value right of up to $5 if anito-cel reaches $6 billion in sales by 2029. Approximately 4.39 million shares have been tendered in the deal, valued at around $7.8 billion, with closing expected in Q2 2026. Separately, Gilead Sciences' long-acting HIV prevention injection faces variable insurer coverage and patient out-of-pocket costs, as it is not yet explicitly covered by the 2023 U.S. task force guidance.
